BACKGROUND: We aimed to develop a multivariable statistical model for risk stratification in patients with chronic heart failure with systolic dysfunction, using patient data that are routinely collected and easily obtained at the time of initial presentation. METHODS AND RESULTS: In a cohort of 2331 patients enrolled in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise TraiNing) study (New York Heart Association class II-IV, left ventricular ejection fraction ≤0.35, randomized to exercise training and usual care versus usual care alone, median follow-up of 2.5 years), we performed risk modeling using Cox proportional hazards models and analyzed the relationship between baseline clinical factors and the primary composite end point of death or all-cause hospitalization and the secondary end point of all-cause death alone. Prognostic relationships for continuous variables were examined using restricted cubic spline functions, and key predictors were identified using a backward variable selection process and bootstrapping methods. For ease of use in clinical practice, point-based risk scores were developed from the risk models. Exercise duration on the baseline cardiopulmonary exercise test was the most important predictor of both the primary end point and all-cause death. Additional important predictors for the primary end point risk model (in descending strength) were Kansas City Cardiomyopathy Questionnaire symptom stability score, higher serum urea nitrogen, and male sex (all P<0.0001). Important additional predictors for the mortality risk model were higher serum urea nitrogen, male sex, and lower body mass index (all P<0.0001). CONCLUSIONS: Risk models using simple, readily obtainable clinical characteristics can provide important prognostic information in ambulatory patients with chronic heart failure with systolic dysfunction. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.
RCT Entities:
BACKGROUND: We aimed to develop a multivariable statistical model for risk stratification in patients with chronic heart failure with systolic dysfunction, using patient data that are routinely collected and easily obtained at the time of initial presentation. METHODS AND RESULTS: In a cohort of 2331 patients enrolled in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise TraiNing) study (New York Heart Association class II-IV, left ventricular ejection fraction ≤0.35, randomized to exercise training and usual care versus usual care alone, median follow-up of 2.5 years), we performed risk modeling using Cox proportional hazards models and analyzed the relationship between baseline clinical factors and the primary composite end point of death or all-cause hospitalization and the secondary end point of all-cause death alone. Prognostic relationships for continuous variables were examined using restricted cubic spline functions, and key predictors were identified using a backward variable selection process and bootstrapping methods. For ease of use in clinical practice, point-based risk scores were developed from the risk models. Exercise duration on the baseline cardiopulmonary exercise test was the most important predictor of both the primary end point and all-cause death. Additional important predictors for the primary end point risk model (in descending strength) were Kansas City Cardiomyopathy Questionnaire symptom stability score, higher serum ureanitrogen, and male sex (all P<0.0001). Important additional predictors for the mortality risk model were higher serum ureanitrogen, male sex, and lower body mass index (all P<0.0001). CONCLUSIONS: Risk models using simple, readily obtainable clinical characteristics can provide important prognostic information in ambulatory patients with chronic heart failure with systolic dysfunction. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.
Authors: H M Krumholz; Y T Chen; V Vaccarino; Y Wang; M J Radford; W D Bradford; R I Horwitz Journal: Am J Cardiol Date: 2000-05-01 Impact factor: 2.778
Authors: Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Kathryn E Flynn; Ileana L Piña; David J Whellan; Li Lin; James A Blumenthal; Stephen J Ellis; Lawrence J Fine; Jonathan G Howlett; Steven J Keteyian; Dalane W Kitzman; William E Kraus; Nancy Houston Miller; Kevin A Schulman; John A Spertus; Christopher M O'Connor; Kevin P Weinfurt Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: Liviu Klein; Barry M Massie; Jeffrey D Leimberger; Christopher M O'Connor; Ileana L Piña; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade Journal: Circ Heart Fail Date: 2008-05 Impact factor: 8.790
Authors: Eileen Hsich; Eiran Z Gorodeski; Randall C Starling; Eugene H Blackstone; Hemant Ishwaran; Michael S Lauer Journal: Circulation Date: 2009-06-15 Impact factor: 29.690
Authors: Jacob P Kelly; Allison Dunning; Phillip J Schulte; Mona Fiuzat; Eric S Leifer; Jerome L Fleg; Lawton S Cooper; Steven J Keteyian; Dalane W Kitzman; Ileana L Pina; William E Kraus; David J Whellan; Christopher M O'Connor; Robert J Mentz Journal: JACC Heart Fail Date: 2016-07-06 Impact factor: 12.035
Authors: Siyun Yang; Monique Anderson Starks; Adrian F Hernandez; Elizabeth L Turner; Robert M Califf; Christopher M O'Connor; Robert J Mentz; Kingshuk Roy Choudhury Journal: Contemp Clin Trials Date: 2019-06-20 Impact factor: 2.226
Authors: Tariq Ahmad; Mona Fiuzat; Benjamin Neely; Megan L Neely; Michael J Pencina; William E Kraus; Faiez Zannad; David J Whellan; Mark P Donahue; Ileana L Piña; Kirkwood F Adams; Dalane W Kitzman; Christopher M O'Connor; G Michael Felker Journal: JACC Heart Fail Date: 2014-06 Impact factor: 12.035
Authors: Maria Chiara Todaro; Bijoy K Khandheria; Timothy E Paterick; Matt M Umland; Vinay Thohan Journal: Curr Cardiol Rep Date: 2014-04 Impact factor: 2.931
Authors: Andrew P Ambrosy; Ankeet S Bhatt; Amanda L Stebbins; Lisa M Wruck; Marat Fudim; Stephen J Greene; William E Kraus; Christopher M O'Connor; Ileana L Piña; David J Whellan; Robert J Mentz Journal: Am Heart J Date: 2018-02-11 Impact factor: 4.749
Authors: Tariq Ahmad; Mona Fiuzat; Daniel B Mark; Ben Neely; Megan Neely; William E Kraus; Dalane W Kitzman; David J Whellan; Mark Donahue; Faiez Zannad; Ileana L Piña; Kirkwood Adams; Christopher M O'Connor; G Michael Felker Journal: Am Heart J Date: 2013-11-04 Impact factor: 4.749
Authors: Kishan S Parikh; Adrian Coles; Phillip J Schulte; William E Kraus; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Mona Fiuzat; David J Whellan; Christopher M O'Connor; Robert J Mentz Journal: Am J Cardiol Date: 2016-07-29 Impact factor: 2.778
Authors: Steven J Keteyian; Eric S Leifer; Nancy Houston-Miller; William E Kraus; Clinton A Brawner; Christopher M O'Connor; David J Whellan; Lawton S Cooper; Jerome L Fleg; Dalane W Kitzman; Alain Cohen-Solal; James A Blumenthal; David S Rendall; Ileana L Piña Journal: J Am Coll Cardiol Date: 2012-10-10 Impact factor: 24.094
Authors: Lauren B Cooper; Robert J Mentz; Jie-Lena Sun; Phillip J Schulte; Jerome L Fleg; Lawton S Cooper; Ileana L Piña; Eric S Leifer; William E Kraus; David J Whellan; Steven J Keteyian; Christopher M O'Connor Journal: Circ Heart Fail Date: 2015-11 Impact factor: 8.790